Meeting
2023 ASCO Annual Meeting
Does serial circulating tumor DNA (ctDNA) monitoring identify additional acquired actionable alterations in metastatic colorectal cancer (mCRC)?
Authors
Jonathan M. Loree
BC Cancer Agency, Vancouver, BC, Canada
Jonathan M. Loree , Adrian Bubie , John H Strickler , Leylah Drusbosky , Scott Kopetz , Kanwal Pratap Singh Raghav
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3540)
DOI
10.1200/JCO.2023.41.16_suppl.3540
Abstract #
3540
Poster Bd #
240
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Genomic landscape of acquired resistance to targeted therapies in metastatic colorectal cancer (mCRC).
First Author: Emily Harrold
Poster
2019 ASCO Annual Meeting
Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA.
First Author: Yoshiaki Nakamura
Poster
2017 Gastrointestinal Cancers Symposium
Blood-based genomic profiling of circulating cell-free tumor DNA (ctDNA) in 1397 patients (pts) with colorectal cancer (CRC).
First Author: John H. Strickler
Poster
2024 ASCO Annual Meeting
Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors.
First Author: Dazhi Liu